Lesko L - Search Results

1

A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches.

Mody H, Ramakrishnan V, Chaar M, Lezeau J, Rump A, Taha K, Lesko L, Ait-Oudhia S. Mody H, et al. Among authors: lesko l. Clin Pharmacol Drug Dev. 2020 Nov;9(8):896-909. doi: 10.1002/cpdd.879. Epub 2020 Oct 6. Clin Pharmacol Drug Dev. 2020. PMID: 33025766 Review.

2

Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.

Kim S, Sharma VD, Lingineni K, Farhan N, Fang L, Zhao L, Brown JD, Cristofoletti R, Vozmediano V, Ait-Oudhia S, Lesko LJ, Trame MN, Schmidt S. Kim S, et al. Among authors: lesko lj. J Clin Pharmacol. 2019 Sep;59(9):1266-1274. doi: 10.1002/jcph.1433. Epub 2019 May 14. J Clin Pharmacol. 2019. PMID: 31087554

3

Regulatory Perspectives in Pharmacometric Models of Osteoporosis.

Madrasi K, Li F, Kim MJ, Samant S, Voss S, Kehoe T, Bashaw ED, Ahn HY, Wang Y, Florian J, Schmidt S, Lesko LJ, Li L. Madrasi K, et al. Among authors: lesko lj. J Clin Pharmacol. 2018 May;58(5):572-585. doi: 10.1002/jcph.1071. Epub 2018 Feb 27. J Clin Pharmacol. 2018. PMID: 29485684 Review.

4

Systems approaches in risk assessment.

Lesko LJ, Zheng S, Schmidt S. Lesko LJ, et al. Clin Pharmacol Ther. 2013 May;93(5):413-24. doi: 10.1038/clpt.2013.29. Epub 2013 Feb 11. Clin Pharmacol Ther. 2013. PMID: 23531724

5

An Integrated Bioinformatics and Quantitative Modeling Approach to Investigate Potential Claims of Oral Generic Drug Product Bioinequivalence: Introduction.

Lesko LJ, Fang L, Schmidt S, Trame MN. Lesko LJ, et al. J Clin Pharmacol. 2019 Sep;59(9):1245-1248. doi: 10.1002/jcph.901. Epub 2019 May 14. J Clin Pharmacol. 2019. PMID: 31087551 No abstract available.

6

To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.

Deng J, Brar SS, Lesko LJ. Deng J, et al. Clin Pharmacol Drug Dev. 2018 Jun;7(5):455-464. doi: 10.1002/cpdd.416. Epub 2017 Dec 2. Clin Pharmacol Drug Dev. 2018. PMID: 29197167

7

Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J. Derendorf H, et al. Among authors: lesko lj. J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1399-418. J Clin Pharmacol. 2000. PMID: 11185661 Review.

8

Individualization of drug therapy: history, present state, and opportunities for the future.

Lesko LJ, Schmidt S. Lesko LJ, et al. Clin Pharmacol Ther. 2012 Oct;92(4):458-66. doi: 10.1038/clpt.2012.113. Epub 2012 Sep 5. Clin Pharmacol Ther. 2012. PMID: 22948891 Review.

9

Is Bioequivalence Established Based on the Reference-Scaled Average Bioequivalence Approach Relevant to Chronic Administration of Phenytoin? Perspectives Based on Population Pharmacokinetic Modeling and Simulations.

Kim H, Fang L, Yu J, Meng Z, Trame MN, Schmidt S, Lesko LJ, Zhao L. Kim H, et al. Among authors: lesko lj. J Clin Pharmacol. 2019 Aug;59(8):1061-1069. doi: 10.1002/jcph.1380. Epub 2019 Feb 4. J Clin Pharmacol. 2019. PMID: 30716169 Clinical Trial.

10

Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.

Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Chang Y, et al. J Clin Pharmacol. 2013 Sep;53(9):962-6. doi: 10.1002/jcph.128. Epub 2013 Jul 7. J Clin Pharmacol. 2013. PMID: 23832278

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

260 results

Search Page